This is a microscopy image of a colon tumor. Credit: Alexandre Calon, IRB Barcelona
About 40-50% of all colorectal patients relapse in the form of metastasis. In the last three years, several molecular classifications have been proposed to identify colorectal cancer patients at risk of relapse. Today in Nature Genetics, scientists headed by ICREA researcher Eduard Batlle at the Institute for Research in Biomedicine (IRB Barcelona) explain why these classifications work and reveal, in fact, that they can be simplified and improved by looking exclusively at the genes that are expressed in the tissue around the tumour, known as the stroma or tumour microenvironment.
"We have re-evaluated the classifications under our perspective and confirmed that colon cancer relapse occurs in patients in which tumour cells have the capacity to disrupt the tissue surrounding the tumour," explains Eduard Batlle, head of the Colorectal Cancer Laboratory at IRB Barcelona. The team of scientists have examined the genetic profile of around 1,000 tumours from patients all over the world. "The conclusion is indisputable. The key to the classifications lies in whether the stroma of the tumour is altered or not and it is this property that confers malignancy to colon tumours. Patients with unaltered stroma are essentially cured after surgery."
This new approach to addressing different types of colon tumour will soon have a practical application for doctors. On one hand, the scientists demonstrate that tumour cells communicate with the stroma through the hormone TGF-beta and that metastasis could be prevented in these patients by interfering with this communication. "We propose exploring the possibility of using TGF-beta inhibitors to treat colon cancer". Several TGF-beta inhibitors are being tested for other kinds of tumours. "The data are impressive. It would be most pertinent for oncologists and pharmaceutical companies to come to an agreement in order to start clinical assays in patients with poor prognosis colon cancer" say Alexandre Calon, postdoctoral researcher and first author of the article. To test the use of these inhibitors, the scientists at IRB Barcelona have developed technology that allows them to grow mini colon tumours in vitro, also known as organoids, from samples taken from patients. "These organoids reproduce the behaviour of the original tumour and are therefore a powerful tool for personalised cancer treatment," explains Batlle.
Furthermore, the IRB Barcelona researchers are very close to achieving a diagnostic test named Colostage to identify those patients at the greatest risk of a relapse in the form of metastasis. "By focusing on the genetic programme of the tissue surrounding the tumour we can identify the vast majority of patients that will experience relapse. This would allow better discrimination of which patients to treat and follow up, as the use of radiotherapy or chemotherapy would benefit only this group" ensures the researcher. In addition, this test will help identify those patients more likely to benefit from the use of TGF-beta inhibitors in clinical trials.
This is a patient-derived tumor organoids: in vitro expansion. Credit: Alexandre Calon, IRB Barcelona
This is a patient derived tumor organoids. Blue: nuclei; red: membrane. Credit: Alexandre Calon, IRB Barcelona
Explore further: Researchers identify a new suppressor of breast metastasis to the lung
More information: Nature Genetics (23 Feb 2014). Advanced online publication DOI: 10.1038/ng.3225
Medical Xpress on facebook
Related Stories
Scientists discover key process that allows colon cancer to metastasize
Nov 12, 2012
A team of 17 researchers, led by scientists Eduard Batlle and Elena Sancho in the Colorectal Cancer Laboratory at the Institute for Research in Biomedicine (IRB Barcelona), have determined that the ability ...
Stem cells may be key to understanding the origins of colon cancer and detecting relapse
Mar 17, 2011
Colorectal cancer cells trigger a set of genes similar to those found in intestinal stem cells, scientists at the Institute for Research in Biomedicine (IRB Barcelona) have found. The team of researchers, led by ICREA researcher ...
Researchers discover one of the mechanisms that prevents the spread of colon cancer
Sep 30, 2007
The first step in the development of colon cancer is the formation of benign tumours, called adenomas, in the intestine. Over time, these tumours may progress to produce colon cancer if they undergo a series of mutations ...
Researchers identify a new suppressor of breast metastasis to the lung
May 27, 2014
A study published today in EMBO Molecular Medicine reveals that the loss of function of the gene RARRES3 in breast cancer cells promotes metastasis to the lung.
Researchers discover a key regulator of colon cancer
Mar 27, 2014
A team headed by Angel R. Nebreda at the Institute for Research in Biomedicine (IRB) identifies a dual role of the p38 protein in colon cancer. The study demonstrates that, on the one hand, p38 is important ...
Recommended for you
Customized DNA rings aid early cancer detection in mice, study finds
52 minutes ago
Imagine: You pop a pill into your mouth and swallow it. It dissolves, releasing tiny particles that are absorbed and cause only cancerous cells to secrete a specific protein into your bloodstream. Two days from now, a finger-prick ...
A standard operation procedure to effectively detect dietetically absorbed plant miRNAs
1 hour ago
In a new study published in the Journal of Nutritional Biochemistry, Chen-Yu Zhang, Xi Chen and Ke Zen's group at Nanjing University systematically characterized the kinetics of plant microRNAs (miRNAs) in human plasma after ...
Cancer survivors make healthier choices than general population
2 hours ago
Cancer survivors make healthier diet and lifestyle choices than the general population, according to a new study.
Palbociclib shows promise in patients with hormone-resistant breast cancer
Feb 20, 2015
Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer ...
Cutting off a cancer cell at its transcriptional source: Model system for designing a small molecule inhibitor
Feb 20, 2015
(Medical Xpress)—What if you could attack cancer cells at their source without hurting the surrounding healthy cells? A group of researchers from the University of Virginia, the University of Massachusetts, ...
Let's talk about sex... after cancer
Feb 20, 2015
Romance may still be lingering in the air, but for many cancer survivors Valentine's Day was just another reminder of how their sexuality has been scarred by cancer.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
This is a microscopy image of a colon tumor. Credit: Alexandre Calon, IRB Barcelona
About 40-50% of all colorectal patients relapse in the form of metastasis. In the last three years, several molecular classifications have been proposed to identify colorectal cancer patients at risk of relapse. Today in Nature Genetics, scientists headed by ICREA researcher Eduard Batlle at the Institute for Research in Biomedicine (IRB Barcelona) explain why these classifications work and reveal, in fact, that they can be simplified and improved by looking exclusively at the genes that are expressed in the tissue around the tumour, known as the stroma or tumour microenvironment.
"We have re-evaluated the classifications under our perspective and confirmed that colon cancer relapse occurs in patients in which tumour cells have the capacity to disrupt the tissue surrounding the tumour," explains Eduard Batlle, head of the Colorectal Cancer Laboratory at IRB Barcelona. The team of scientists have examined the genetic profile of around 1,000 tumours from patients all over the world. "The conclusion is indisputable. The key to the classifications lies in whether the stroma of the tumour is altered or not and it is this property that confers malignancy to colon tumours. Patients with unaltered stroma are essentially cured after surgery."
This new approach to addressing different types of colon tumour will soon have a practical application for doctors. On one hand, the scientists demonstrate that tumour cells communicate with the stroma through the hormone TGF-beta and that metastasis could be prevented in these patients by interfering with this communication. "We propose exploring the possibility of using TGF-beta inhibitors to treat colon cancer". Several TGF-beta inhibitors are being tested for other kinds of tumours. "The data are impressive. It would be most pertinent for oncologists and pharmaceutical companies to come to an agreement in order to start clinical assays in patients with poor prognosis colon cancer" say Alexandre Calon, postdoctoral researcher and first author of the article. To test the use of these inhibitors, the scientists at IRB Barcelona have developed technology that allows them to grow mini colon tumours in vitro, also known as organoids, from samples taken from patients. "These organoids reproduce the behaviour of the original tumour and are therefore a powerful tool for personalised cancer treatment," explains Batlle.
Furthermore, the IRB Barcelona researchers are very close to achieving a diagnostic test named Colostage to identify those patients at the greatest risk of a relapse in the form of metastasis. "By focusing on the genetic programme of the tissue surrounding the tumour we can identify the vast majority of patients that will experience relapse. This would allow better discrimination of which patients to treat and follow up, as the use of radiotherapy or chemotherapy would benefit only this group" ensures the researcher. In addition, this test will help identify those patients more likely to benefit from the use of TGF-beta inhibitors in clinical trials.
This is a patient-derived tumor organoids: in vitro expansion. Credit: Alexandre Calon, IRB Barcelona
This is a patient derived tumor organoids. Blue: nuclei; red: membrane. Credit: Alexandre Calon, IRB Barcelona
Explore further: Researchers identify a new suppressor of breast metastasis to the lung
More information: Nature Genetics (23 Feb 2014). Advanced online publication DOI: 10.1038/ng.3225
Medical Xpress on facebook
Related Stories
Scientists discover key process that allows colon cancer to metastasize
Nov 12, 2012
A team of 17 researchers, led by scientists Eduard Batlle and Elena Sancho in the Colorectal Cancer Laboratory at the Institute for Research in Biomedicine (IRB Barcelona), have determined that the ability ...
Stem cells may be key to understanding the origins of colon cancer and detecting relapse
Mar 17, 2011
Colorectal cancer cells trigger a set of genes similar to those found in intestinal stem cells, scientists at the Institute for Research in Biomedicine (IRB Barcelona) have found. The team of researchers, led by ICREA researcher ...
Researchers discover one of the mechanisms that prevents the spread of colon cancer
Sep 30, 2007
The first step in the development of colon cancer is the formation of benign tumours, called adenomas, in the intestine. Over time, these tumours may progress to produce colon cancer if they undergo a series of mutations ...
Researchers identify a new suppressor of breast metastasis to the lung
May 27, 2014
A study published today in EMBO Molecular Medicine reveals that the loss of function of the gene RARRES3 in breast cancer cells promotes metastasis to the lung.
Researchers discover a key regulator of colon cancer
Mar 27, 2014
A team headed by Angel R. Nebreda at the Institute for Research in Biomedicine (IRB) identifies a dual role of the p38 protein in colon cancer. The study demonstrates that, on the one hand, p38 is important ...
Recommended for you
Customized DNA rings aid early cancer detection in mice, study finds
52 minutes ago
Imagine: You pop a pill into your mouth and swallow it. It dissolves, releasing tiny particles that are absorbed and cause only cancerous cells to secrete a specific protein into your bloodstream. Two days from now, a finger-prick ...
A standard operation procedure to effectively detect dietetically absorbed plant miRNAs
1 hour ago
In a new study published in the Journal of Nutritional Biochemistry, Chen-Yu Zhang, Xi Chen and Ke Zen's group at Nanjing University systematically characterized the kinetics of plant microRNAs (miRNAs) in human plasma after ...
Cancer survivors make healthier choices than general population
2 hours ago
Cancer survivors make healthier diet and lifestyle choices than the general population, according to a new study.
Palbociclib shows promise in patients with hormone-resistant breast cancer
Feb 20, 2015
Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer ...
Cutting off a cancer cell at its transcriptional source: Model system for designing a small molecule inhibitor
Feb 20, 2015
(Medical Xpress)—What if you could attack cancer cells at their source without hurting the surrounding healthy cells? A group of researchers from the University of Virginia, the University of Massachusetts, ...
Let's talk about sex... after cancer
Feb 20, 2015
Romance may still be lingering in the air, but for many cancer survivors Valentine's Day was just another reminder of how their sexuality has been scarred by cancer.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment